Escherichia coli-induced granulomatous colitis in a cat

Isao Matsumoto1,2, Ko Nakashima1, Hajime Morita1, Koichi Kasahara1, Osamu Kataoka3 and Kazuyuki Uchida2

Abstract

Case summary A 10-year-old castrated male domestic shorthair cat presented with a 6 month history of diarrhoea that responded poorly to medical treatment. Ultrasonography revealed moderate thickening of the colonic wall (4.8 mm) and right colic and jejunal lymphadenomegalies. Endoscopic examination revealed partial circumferential narrowing of the transverse colon and friable colonic mucosa with multiple haemorrhagic regions. Histopathological and immunohistochemical examinations revealed a large number of Escherichia coli phagocytosed by periodic acid–Schiff-positive macrophages. Bacterial culture also yielded enrofloxacin-sensitive E coli. The cat was initially treated with prednisolone, which resulted in little improvement. Following histopathological examination and bacterial culture, treatment with enrofloxacin was commenced. Antibacterial therapy resulted in remission of the diarrhoea and an increase in body weight within 14 days.

Relevance and novel information Granulomatous colitis (GC) or histiocytic ulcerative colitis has been rarely described in cats. There has only been one previously published case study involving a cat, and the aetiology remains largely unknown. The current article describes the regression of E coli-related GC following antibacterial treatment in a cat. Clinical signs, histopathological appearance and response to enrofloxacin were similar to those in canine GC. The current findings suggest that E coli also plays an important role in the development of feline GC.

Keywords: E coli; enrofloxacin; granulomatous colitis

Accepted: 11 February 2019
and 10.4 mm × 6.1 mm, respectively). Endoscopic examination revealed partial circumferential narrowing of the transverse colon and friable colonic mucosa with multiple haemorrhagic regions (Figure 2). The mucosa of the duodenum and jejunum was mildly oedematous. The thickness of the oesophageal and gastric mucosa was within normal limits. Mucosal tissue specimens were obtained from the stomach, duodenum and colon. The collected tissue samples were fixed in 10% buffered formalin and subjected to histopathological examination.

Histological examination with haematoxylin and eosin staining (HE) revealed marked ulceration of the colonic mucosa; marked alteration in the normal glandular architecture was observed in the lamina propria (Figure 3). The lesions consisted of marked transmural infiltration of foamy macrophages accompanied by neutrophils, plasma cells and lymphocytes (Figure 4). Apart from the colonic lesion, marked infestation of mucosa spirochetes was observed in the stomach. Duodenal lesions were unremarkable. A provisional diagnosis of granulomatous colitis (GC) was made based on the histopathological appearance (HE) at day 7.

Owing to its rarity in cats, additional stains and immunohistochemistry were performed for definitive
diagnosis. The infiltrating macrophages were predominantly periodic acid–Schiff (PAS) positive (Figure 5). Warthin–Starry, Ziehl–Neelsen and gram stains identified intracytoplasmic non-acid-fast, gram-negative bacilli in the macrophages on tissue section (Figure 6). The infiltration of macrophages and *Escherichia coli* colonisation were further confirmed by immunohistochemical analyses. Immunohistochemistry revealed marked infiltration of CD204+ Iba-1+ macrophages and colonisation of *E coli* in the granulomatous lesions (Figure 7). In view of these findings, a final diagnosis of GC was made at day 21.

At day 0, prior to a definitive diagnosis of GC with histopathology and immunohistochemistry, the cat was initially treated with prednisolone (1 mg/kg q24h), famotidine (1 mg/kg q24h), metoclopramide (0.25 mg/kg q12 h) and probiotics (*Streptococcus faecalis* 129 BIO 3B-R [Biofermin-R; Biofermin Pharmaceutical]; half tablet q24h) for 4 weeks. The cat was fed a therapeutic diet (Renal Support; Royal Canin). The initial treatment appeared to only partially improve clinical signs. The cat had semi-formed stools twice daily, with inconsistent solid stools. Body weight decreased from 4.75 kg to 4.45 kg within the first 28 days of treatment.

Following the definitive diagnosis, additional colonscopic tissue sampling was performed for bacterial culture and sensitivity at day 28. After saline wash, a homogenised sample was subjected to bacterial culture. Attempts to isolate bacteria on culture media yielded enrofloxacin-sensitive *E coli* (2+). Treatment with enrofloxacin was also initiated at day 28. The animal was prescribed enrofloxacin (5 mg/kg q24h for 13 weeks), as recommended in dogs,1 prednisolone (0.5 mg/kg q24h for 5 weeks), famotidine (1 mg/kg q24h for 2 weeks), metoclopramide (0.25 mg/kg q12h for 13 weeks) and the aforementioned probiotic half-tablet (q24h for 13 weeks). The cat more consistently produced solid or semi-formed stools once daily and its body weight increased to 4.75 kg by day 42.

The cat’s body weight increased to 5.0 kg and formed solid stools twice daily by day 63. Although ultrasound examinations at day 119 showed persistent wall thickening of the ascending and transverse colon (4.6 mm), enrofloxacin was discontinued because the thickness of the right colic lymph nodes was within the normal limit. At day 207, approximately 3 months after cessation of the first course of enrofloxacin, recurrent diarrhoea was noted once every 3 days. Upon examination at day 234,
the cat’s body weight was found to have decreased to 4.8 kg. Ultrasonography revealed thickening of the ascending and transverse colonic wall (4.6 mm), and moderately enlarged right colic lymph nodes (8 mm). Serum biochemical tests revealed increased creatinine (3.4 mg/dl) and urea nitrogen (34.5 mg/dl) levels. The cat was treated with enrofloxacin (5 mg/kg q24h for 15 weeks and q48h for the following 8 weeks). Faecal consistency dramatically improved by day 244. However, the cat experienced another episode of diarrhoea at day 751, approximately 12 months after cessation of the second course of enrofloxacin. Enrofloxacin was reinitiated (5 mg/kg q24h for 4 weeks) and a positive clinical response was noted by day 755.

The cat has been free of clinical signs for the following 7 months and has been off enrofloxacin without recurrence for 5 months (day 950). Enrofloxacin-associated retinal degeneration was not observed in the current case.

Discussion
An enteropathy called GC, or histiocytic ulcerative colitis, is characterised by granulomatous inflammation of the colonic mucosa, lamina propria and submucosa, with marked transmural infiltration of PAS-positive macrophages.2,3 PAS-positive material is considered to be glycoprotein from bacterial cell walls.4 GC has been frequently reported in dogs; however, only a limited number of cases have been reported in cats.4 Clinical presentation, and macroscopic and microscopic findings in the present study were consistent with those described in dogs.2,3,5 In canine cases, macrophage heterogeneity suggests a difference in function compared with healthy individuals.6

Although the pathogenesis is not well understood, recent studies have identified _Escherichia coli_ in canine patients.2,5,7,8 There are phylogenetic similarities between the _E coli_ strain obtained from Boxer dog GC, and adherent and invasive _E coli_ (AIEC) in human Crohn’s disease.8 AIEC is able to replicate within epithelial cells and macrophages without inducing host cell death.9 AIEC has been isolated from the feline intestine at an exceptionally high frequency (82%),10 and the association between AIEC and feline GC needs to be further investigated. In the current case, identification of _E coli_ in the granulomatous lesion was consistent with a previous feline study that reported bacilli within the phagocytic vacuoles of macrophages.4 Although not performed in the current case study, identification of the _E coli_ strain and repeated histopathological evaluation would be valuable to understanding the nature of feline GC.

As demonstrated in canine case studies,11 regression of clinical signs following antibacterial treatment in the present case suggests a critical role of _E coli_ in feline GC. The cat responded well to intermittently administered enrofloxacin when it had semi-formed stools or diarrhoea. Dramatic improvement in faecal consistency was noted within 2 weeks of antibacterial treatment, which is consistent with previous investigations involving dogs.1 In dogs, at least 6–8 weeks of treatment at doses of 5–10 mg/kg body weight q24h is recommended.1 However, response to antibacterials varies among individual dogs,1,11 and it appears that antibacterial resistance significantly affects clinical outcomes.12 Although the current single case was insufficient to determine the factors affecting clinical outcomes in cats, a future case series would help in determining the optimal use of antibacterials in feline GC.

Over-representation of the Boxer dog breed suggests that GC might be a breed-specific disease; however, it has also been reported in other canine breeds.2,5,7,13–16 While dogs <4 years of age are typically affected by GC,2 in this case and the other case study middle-aged cats were affected.4 The rarity of the disease in cats may suggest variation in hereditary susceptibility to _E coli_-related GC between dogs and cats.

The present case report described the case of a cat with _E coli_-related GC that regressed following long-term treatment with enrofloxacin. Clinical presentation, and endoscopic and microscopic findings closely resembled those described in dogs. Immunohistochemically, _E coli_ was detected within granulomatous lesions, and resolution of gastrointestinal clinical signs following antibacterial treatment may reflect the critical role of _E coli_ in feline GC. The rarity of the disease in cats may suggest substantial differences in host susceptibility to _E coli_-induced GC. Together with our findings, additional cases will enable a better understanding of the clinical nature of GC in cats.

Conclusions
GC should be included in the differential diagnoses in feline cases with marked submucosal infiltration of macrophages in the colon that respond poorly to immunosuppressive and dietary treatment. In such cases, further immunohistochemical identification of _E coli_ and treatment with enrofloxacin may be suggested.

Conflict of interest
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

References
1 Mansfield CS, James FE, Craven M, et al. Remission of histiocytic ulcerative colitis in Boxer dogs correlates with eradication of invasive intramucosal _Escherichia coli_. J Vet Intern Med 2009; 23: 964–969.
2 Van Kruiningen HJ, Montali RJ, Strandberg JD, et al. A granulomatous colitis of dogs with histologic resemblance to Whipple’s disease. _Path Vet_ 1965; 2: 521–544.
3 Gomez JA, Russell SW, Trowbridge JO, et al. Canine histiocytic ulcerative colitis. An ultrastructural study of the early mucosal lesion. Am J Dig Dis 1977; 22: 485–496.
4 Van Kruiningen HJ and Dobbins WO 3rd. Feline histiocytic colitis. A case report with electron microscopy. Vet Pathol 1979; 16: 215–222.
5 Carvallo FR, Kerlin R, Fredette C, et al. Histiocytic typhlocolitis in two colony Beagle dogs. Exp Toxicol Pathol 2015; 67: 219–221.
6 Nolte A, Junginger J, Baum B, et al. Heterogeneity of macrophages in canine histiocytic ulcerative colitis. Innate Immun 2017; 23: 228–239.
7 Manchester AC, Hill S, Sabatino B, et al. Association between granulomatous colitis in French Bulldogs and invasive Escherichia coli and response to fluoroquinolone antimicrobials. J Vet Intern Med 2013; 27: 56–61.
8 Simpson KW, Dogan B, Rishniw M, et al. Adherent and invasive Escherichia coli is associated with granulomatous colitis in boxer dogs. Infect Immun 2006; 74: 4778–4792.
9 Glasser AL, Boudeau J, Barnich N, et al. Adherent invasive Escherichia coli strains from patients with Crohn’s disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001; 69: 5529–5537.
10 Martinez-Medina M, Garcia-Gil J, Barnich N, et al. Adherent-invasive Escherichia coli phenotype displayed by intestinal pathogenic E. coli strains from cats, dogs, and swine. Appl Environ Microbiol 2011; 77: 5813–5817.
11 Hostutler RA, Luria BJ, Johnson SE, et al. Antibiotic-responsive histiocytic ulcerative colitis in 9 dogs. J Vet Intern Med 2004; 18: 499–504.
12 Craven M, Dogan B, Schukken A, et al. Antimicrobial resistance impacts clinical outcome of granulomatous colitis in boxer dogs. J Vet Intern Med 2010; 24: 819–824.
13 Craven M, Mansfield CS and Simpson KW. Granulomatous colitis of boxer dogs. Vet Clin North Am Small Anim Pract 2011; 41: 433–445.
14 Stokes JE, Kruger JM, Mullaney T, et al. Histiocytic ulcerative colitis in three non-boxer dogs. J Am Anim Hosp Assoc 2001; 37: 461–465.
15 Tanaka H, Nakayama M and Takase K. Histiocytic ulcerative colitis in a French bulldog. J Vet Med Sci 2003; 65: 431–433.
16 Van der Gaag I, Van Toorenburg JV, Voorhout G, et al. Histiocytic ulcerative colitis in a French Bulldog. J Small Anim Pract 1978; 19: 283–290.